Provided by the Annenberg Center for Health Sciences at Eisenhower
Supported by educational grants from Gilead Sciences, Lilly, and Sanofi Genzyme and Regeneron Pharmaceuticals.
This expert-led CME-certified activity provides a comprehensive review of key rheumatoid arthritis data from EULAR* and more, including:
Can we safely taper corticosteroids after treatment with biologic DMARDs?
Should we attempt to withdraw MTX after treatment with biologic DMARDs or JAK inhibitors?
What are the clinical implications of the latest data on new and emerging JAK inhibitors?
What does the future hold for investigational small molecule inhibitors?
This program is intended for physicians and other healthcare providers who care for patients with RA.
Upon completion of this activity, participants should be able to:
Identify key findings from real-world experience in the management of TNF inhibitor–refractory patients with RA
Describe outcomes from RA studies of biologic and targeted DMARD therapy initiated early in the disease course
Summarize clinical trial results and potential applications of emerging therapies for RA
Conflict Of Interest Disclosure Policy
The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME/CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Stanley B. Cohen, MD Clinical Professor Department of Internal Medicine University of Texas Southwestern Medical School Co-Director Division of Rheumatology Presbyterian Hospital Co-Medical Director Metroplex Clinical Research Center Dallas, Texas
Dr. Cohen has disclosed that he has received consulting fees and funds for research support from AbbVie, Amgen, Gilead Sciences, Lilly, and Pfizer.
Jonathan Kay, MD Professor of Medicine and Population & Quantitative Health Sciences Timothy S. and Elaine L. Peterson Chair in Rheumatology Division of Rheumatology Department of Medicine University of Massachusetts Medical School Physician Division of Rheumatology Department of Medicine UMass Memorial Medical Center Worcester, Massachusetts
Dr. Kay has disclosed that he has he has received consulting fees from AbbVie, Boehringer Ingelheim, Celltrion, Horizon, Kolon TissueGene, Merck Sharp and Dohme, MorphoSys, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, and Union Chimique Belge and funds for research support from Gilead Sciences, Pfizer, and Union Chimique Belge.
Accredited Provider Disclosures
Charles E. Willis, Director of Continuing Education; Amanda Sewell, MBA, Manager of Continuing Education and Melissa Velasquez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.
Publishing Staff Disclosures
Zachary Schwartz, MSc, Carolyn Skoronski, PharmD and Tiffany Hensley-McBain, PhD of Clinical Care Options have no relevant conflicts of interest to report. Joy Curzio has disclosed that she has ownership interests in Advaxis, Editas and OnoSec.
The PIM planners and managers have nothing to disclose.
AMA PRA Category 1 Credit(s)TM
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate.
Your online certificate will be saved and accessible on the Clinical Care Options website and will not be saved to your myCME CME History.